Dyskinesier ved Parkinsons sygdom: opdatering om nye billeddannende metoder og behandlingsmuligheder

TY - JOUR

T1 - Dyskinesier ved Parkinsons sygdom: opdatering om nye billeddannende metoder og behandlingsmuligheder

AU - Thomsen, Birgitte Liang Chen

AU - Herz, Damian Marc

AU - Siebner, Hartwig Roman

AU - Løkkegaard, Annemette

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Levodopa-induced dyskinesia (LID) represents a severe adverse effect of long-term treatment of Parkinson's disease with levodopa. Neuroimaging studies have contributed to our understanding of LID and may help to identify patients at risk of developing LID. Amantadine can be used for the treatment of LID, and novel drugs are under development. Deep brain stimulation of the subthalamic nucleus and globus pallidus internus alleviates LID, the former indirectly by reducing levodopa intake, the latter through direct effects. Repetitive transcranial magnetic stimulation has been shown to transiently improve LID.

AB - Levodopa-induced dyskinesia (LID) represents a severe adverse effect of long-term treatment of Parkinson's disease with levodopa. Neuroimaging studies have contributed to our understanding of LID and may help to identify patients at risk of developing LID. Amantadine can be used for the treatment of LID, and novel drugs are under development. Deep brain stimulation of the subthalamic nucleus and globus pallidus internus alleviates LID, the former indirectly by reducing levodopa intake, the latter through direct effects. Repetitive transcranial magnetic stimulation has been shown to transiently improve LID.

M3 - Tidsskriftartikel

C2 - 28263159

SN - 0041-5782

VL - 179

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V06160433

ER -